The PERMET trial evaluated the effectiveness of metformin on walking performance in adults aged 50 and older with peripheral artery disease (PAD) who do not have diabetes. Conducted across four US sites from May 2017 to February 2025, the study found no significant changes in 6-minute walk distance between metformin and placebo groups after six months. Despite previous studies suggesting benefits, this trial concluded metformin does not improve walking in PAD patients. Adverse events were similar, with gastrointestinal issues being most common among metformin users.
1. PERMET trial studied metformin's effect on adults with PAD without diabetes. 2. 202 participants were enrolled across 4 US sites from May 2017 to February 2025. 3. No significant improvement in walking distance observed at 6 months. 4. Common adverse events included indigestion/stomach upset. 5. 89% of participants completed the trial. 6. Results contradicted earlier studies suggesting metformin benefits. 7. Trial funded by National Heart, Lung, and Blood Institute.
Listen Tab content
